Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.58 |
| ▸ | FYN | P06241 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | ITK | Q08881 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 5/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826974 | 0.87 | FYN (0.54) | BTKFYNEGFRLCKJAK3 | |
| SCHEMBL15826973 | 0.81 | FYN (0.57) | BTKFYNEGFRLCKJAK3 | |
| SCHEMBL16285723 | 0.77 | BTK (0.64) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL14471386 | 0.75 | PIK3CD (0.63) | BTKFYNEGFRSRCABL1 | |
| SCHEMBL13183365 | 0.74 | SRC (0.57) | BTKFYNEGFRLCKJAK3 | |
| SCHEMBL13860104 | 0.74 | BTK (1.00) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL13860105 | 0.74 | BTK (1.00) | BTKEGFRLCKJAK3ITK | |
| SCHEMBL15826968 | 0.73 | PIK3CD (0.73) | BTKFYNEGFRSRCABL1 | |
| SCHEMBL13860158 | 0.73 | BTK (1.00) | BTK | |
| SCHEMBL13860157 | 0.73 | BTK (1.00) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | BTK 4/4885FYN 28/4885EGFR 21/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | BTK 156/4885FYN 891/4885EGFR 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.